Table 2.
Treatment characteristics in ICU patients
| Treatment | Survivors (N = 16) |
Non-survivors (N = 12) |
P value |
|---|---|---|---|
| Tocilizumab N(%) | 4 (25) | 4 (25) | 0.6908 |
| Remdesivir N(%) | 3 (18.8) | 4 (5) | 0.6618 |
| Hydroxychloroquine N(%) | 12 (75) | 12 (100) | 0.1131 |
| Ritonavir/Lopinavir N(%)a | 7 (50) | 9 (75) | 0.1358 |
| Corticosteroids N(%)b | |||
| - Dexamethasone 0.4 mg·Kg− 1 | 4 (25) | 5(42) | 0.4319 |
| - Methylprednisolone 0.3 mg·Kg−1 | 0 (0) | 1(8.3) | 0.4286 |
| - Hydrocortisone 150 mg·die−1 | 1 (6.25) | 1(8.3) | > 0.999 |
| Mechanical ventilationc | |||
| - Vt/IBW -ml Kg−1d | 7.85(7.6–8.85) | 6.4 (6.1–8) | 0.4275 |
| - PEEP -cmH20 | 11(8–13.25) | 12 (8–12) | 0.9073 |
aData regarding the administration of Ritonavir/Lopinavir are missing for two patients who died and two who survived (14.8%)
bData regarding the administration of steroids is missing for one dead patient (3.70%)
cData regarding ventilation parameters are missing of two dead patients (7.41%)
dVt/IBW Tidal volume/ideal body weight calculated using the gender-specific Acute Respiratory Distress Syndrome Network (ARDSnet) formulas [8]